Vicore Pharma Holding AB (publ)
SSE:VICO.ST
14.38 (SEK) • At close February 20, 2024
Overview | Financials
Numbers are in millions (except for per share data and ratios) SEK.
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue
| 0 | 0 | 0 | 0 | 0 | 0.508 | 0.932 | 0.852 | 0.84 | 1.571 | 3.305 | 0.003 |
| Cost of Revenue
| 3.421 | 3.612 | 3.598 | 3.537 | 1.338 | 21.756 | -2.645 | -1.221 | -0.816 | -0.72 | -0.72 | 0.003 |
| Gross Profit
| -3.421 | -3.612 | -3.598 | -3.537 | -1.338 | -21.248 | 3.577 | 2.073 | 1.656 | 2.291 | 4.025 | 0 |
| Gross Profit Ratio
| 0 | 0 | 0 | 0 | 0 | -41.827 | 3.838 | 2.433 | 1.971 | 1.458 | 1.218 | 0.102 |
| Reseach & Development Expenses
| 276.294 | 249.965 | 271.812 | 142.021 | 67.048 | 20.463 | 17.555 | 12.257 | 3.868 | 0 | 0 | 0 |
| General & Administrative Expenses
| 36.923 | 28.38 | 20.204 | 24.986 | 26.875 | 8.624 | 5.431 | 5.006 | 3.36 | 4.042 | 2.854 | 0 |
| Selling & Marketing Expenses
| 7.672 | 9.149 | 1.404 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| SG&A
| 44.595 | 37.529 | 21.608 | 24.986 | 26.875 | 8.624 | 5.431 | 5.006 | 3.36 | 4.042 | 2.854 | 0.003 |
| Other Expenses
| 0.617 | 0 | 0 | -17.536 | 0.091 | 13.007 | 10.529 | 3.716 | 2.839 | 1.656 | -0.16 | 0 |
| Operating Expenses
| 321.506 | 287.494 | 293.42 | 149.471 | 94.014 | 42.094 | 15.96 | 8.722 | 6.199 | 5.698 | 2.694 | 0.003 |
| Operating Income
| -321.506 | -290.725 | -294.818 | -149.538 | -94.014 | -44.28 | -12.793 | -6.649 | -4.543 | -5.34 | -2.995 | -0.002 |
| Operating Income Ratio
| 0 | 0 | 0 | 0 | 0 | -87.165 | -13.726 | -7.804 | -5.408 | -3.399 | -0.906 | -0.537 |
| Total Other Income Expenses Net
| 10.18 | 1.919 | -1.917 | 2.223 | 0.685 | 19.905 | -0.472 | -0.003 | -0.027 | 18.665 | 0.371 | -0.001 |
| Income Before Tax
| -311.326 | -288.806 | -296.735 | -147.315 | -93.329 | -21.681 | -12.855 | -6.652 | -4.57 | 13.687 | -1.603 | -0.003 |
| Income Before Tax Ratio
| 0 | 0 | 0 | 0 | 0 | -42.679 | -13.793 | -7.808 | -5.44 | 8.712 | -0.485 | -0.953 |
| Income Tax Expense
| 0.384 | -0.384 | -0.254 | -0.453 | -0.245 | 20.257 | -0.41 | 0 | 0 | 18.77 | 0.59 | 0 |
| Net Income
| -310.942 | -288.422 | -296.481 | -146.862 | -93.084 | -21.681 | -12.855 | -6.652 | -4.57 | 13.687 | -1.603 | -0.003 |
| Net Income Ratio
| 0 | 0 | 0 | 0 | 0 | -42.679 | -13.793 | -7.808 | -5.44 | 8.712 | -0.485 | -0.953 |
| EPS
| -3.22 | -3.99 | -4.25 | -2.71 | -2.16 | -0.95 | -0.76 | -0.47 | -0.32 | 1.06 | -0.12 | -0.092 |
| EPS Diluted
| -3.22 | -3.99 | -4.25 | -2.71 | -2.16 | -0.95 | -0.76 | -0.47 | -0.32 | 1.06 | -0.12 | -0.092 |
| EBITDA
| -317.466 | -286.201 | -291.005 | -145.186 | -92.513 | -25.006 | -12.786 | -6.643 | -4.537 | 13.828 | -1.344 | -0.002 |
| EBITDA Ratio
| 0 | 0 | 0 | 0 | 0 | -49.224 | -13.719 | -7.797 | -5.401 | 8.802 | -0.407 | -0.526 |